Skip to content

Price / sales at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
0.2×-0.1×
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
1.2×-0.3×
PTH
Pelthos Therapeutics Inc.PTHS
2.5×
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-1.7×
HRO
HarrowHROW
4.9×+0.4×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
5.1×-0.4×

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Calculated from Journey Medical Corporation’s reported figures.

Based on the most recent quarter.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's price / sales?
Journey Medical Corporation (DERM) reported price / sales of 2× in Q1 2026.
How has Journey Medical Corporation's price / sales changed year-over-year?
Journey Medical Corporation's price / sales decreased by 18.2% year-over-year, from 2.4× to 2×.
What is the long-term trend for Journey Medical Corporation's price / sales?
Over 4 years (2021 to 2025), Journey Medical Corporation's price / sales has grown at a 23.0% compound annual growth rate (CAGR), from 1.5× to 3.4×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.